A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by activating the mother’s immune system to produce defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence indicating that a two-week gap is adequate to shield babies born slightly early. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when immunised 4 weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from day one
- Coverage possible with two-week gap before early delivery
- Vaccination in third trimester still offers meaningful infant protection
Persuasive evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been confirmed through a comprehensive study carried out throughout England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that six-month period, providing robust and representative data of the vaccine’s practical effectiveness. The study’s findings have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and prospective parents with trust in the vaccine’s established performance across varied populations and settings.
The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This clear distinction underscores the vaccine’s essential role in preventing serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology captured actual clinical results rather than experimental conditions, providing tangible evidence of how the vaccine works when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and its risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection triggers deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to feed and breathe adequately. Parents frequently observe their babies struggling visibly, their chests rising whilst they attempt to draw enough air into their weakened respiratory system. Whilst most newborns recover with palliative treatment, a limited though important proportion perish from respiratory syncytial virus complications annually, making immunisation programmes a critical public health objective for safeguarding the youngest and most vulnerable people in our communities.
- RSV triggers inflammation in lungs, causing severe breathing difficulties in infants
- Approximately half of infants acquire the infection in their first few months of life
- Symptoms span from minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- More than 20,000 UK infants need serious hospital treatment for RSV annually
- Small numbers of babies succumb to RSV complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The communication from health authorities stays clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among eligible pregnant women, whilst others continue working to increase awareness and access to the jab. These geographical variations demonstrate variations in healthcare infrastructure, communication strategies, and local engagement efforts, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts rolling out varied communication campaigns to engage with pregnant women
- Geographic variations in vaccine uptake rates across England necessitate strategic intervention
- Local healthcare systems modifying schemes to meet local requirements and situations
Real-world impact and parental perspectives
The vaccine’s outstanding effectiveness translates into concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this protective measure, the 80% drop in admissions means thousands of infants protected against critical disease. Parents no longer face the distressing scenario of watching their newborns gasping for air or struggle to eat, symptoms that define critical RSV illness. The vaccine has markedly changed the picture of neonatal respiratory health, offering expectant mothers a proactive tool to shield their most at-risk babies during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused profound brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s promotion of the jab underscores the profound consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now offered protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to expectant mothers during their late pregnancy, transforming what was once an inevitable seasonal threat into a controllable health concern.